Unlocking New Opportunities for Oncology Innovation
A UK-based biotech company needed to find the right partners to out-license two promising oncology assets in Phase 1 and Phase 2 development. Previous outreach efforts had fallen short, and the company lacked the internal resources to identify and engage suitable partners at scale.
That’s where Evaluate’s Business Development & Licensing (BD&L) consulting team stepped in, bringing deep industry expertise, robust data, and a proven methodology to deliver results.
The Challenge
- Identify and prioritize potential partners from a pool of over 1,000 companies
- Develop a quantitative assessment methodology for partner selection
- Execute tailored outreach to maximize engagement and deal potential
Our Approach
- Data-Driven Partner Prioritization: Using proprietary databases like Evaluate Pharma, our team built a dynamic model to compare and rank potential partners by a range of criteria, including, therapy focus, clinical development strength, and geographical reach.
- Strategic Outreach: After collaborating with the client to select the top 50 targets, we identified key decision-makers, such as Heads of Partnering and VPs of Business Development, and crafted tailored communications that aligned the assets’ value with each company’s pipeline and goals.
- Transparent Feedback: For companies not ready to move forward, we shared actionable feedback, helping the client refine future outreach and partnership strategies.
The Impact
- 50 companies targeted with personalized outreach
- 30% response rate – well above industry benchmarks
- 3 major pharma companies actively reviewing the assets for licensing
